LEXINGTON, KY, May 02, 2018 -- Rhino Resource Partners LP (OTCQB: RHNO) (“Rhino” or the “Partnership”) today announced that it plans to release its 2018 first quarter financial results on Wednesday, May 9, 2018 before the market opens. The Partnership will not host a conference call this quarter and any inquiries can be made to Rhino’s investor relations department.
About Rhino Resource Partners LP
Rhino Resource Partners LP is a diversified energy limited partnership that is focused on coal and energy related assets and activities, including energy infrastructure investments. Rhino produces metallurgical and steam coal in a variety of basins throughout the United States.
Additional information regarding Rhino is available at its web site – RhinoLP.com.
Investor Contact: Scott Morris +1 859.519.3622 [email protected]


Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 



